These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17850826)

  • 1. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
    Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
    Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.
    Hori M; Iwama T; Asakura Y; Kawanishi M; Kamon J; Hoshino A; Takahashi S; Takahashi K; Nakaike S; Tsuruzoe N
    Eur J Pharmacol; 2009 Sep; 618(1-3):63-9. PubMed ID: 19616537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
    J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
    Yoshida H; Itoh S; Hara T; Sasaki Y; Kondo S; Nakagawa T; Asanuma A; Tanabe S
    Atherosclerosis; 2012 Mar; 221(1):84-90. PubMed ID: 22269153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol: treatment of intermittent claudication.
    Reilly MP; Mohler ER
    Ann Pharmacother; 2001 Jan; 35(1):48-56. PubMed ID: 11197586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
    Nakai K; Takenobu Y; Takimizu H; Akimaru S; Maegawa H; Ito H; Marsala M; Katsube N
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):253-63. PubMed ID: 14518565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion.
    Orito K; Kishi M; Fujiki H; Nakazawa T; Imaizumi T; Kimura Y; Mori T; Kambe T
    J Pharmacol Toxicol Methods; 2004; 49(1):25-9. PubMed ID: 14670691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterases as targets for intermittent claudication.
    Liu Y; Shakur Y; Kambayashi J
    Handb Exp Pharmacol; 2011; (204):211-36. PubMed ID: 21695642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilostazol: a novel treatment option in intermittent claudication.
    Cariski AT
    Int J Clin Pract Suppl; 2001 Apr; (119):11-8. PubMed ID: 11355274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
    Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
    Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
    Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options in intermittent claudication: the US experience.
    Hiatt WR
    Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cilostazol (Pletal) in the management of intermittent claudication.
    Bradbury AW
    Int J Clin Pract; 2003 Jun; 57(5):405-9. PubMed ID: 12846346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.